News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Additional Listing and Total Voting Rights
Released   14:30 11-Oct-2010
Number     1946U14

FOR IMMEDIATE RELEASE

London, 11 October 2010

ADDITIONAL LISTING AND TOTAL VOTING RIGHTS
PICTET INCREASE HOLDING TO OVER 3%

ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"), the specialist discovery and development pharmaceutical company announces that following the exercise of options held by the liquidators to Dawnay Day Corporate Finance Limited, application has been made to the London Stock Exchange for the admission of 441,000 new ordinary shares of 10 pence each in the Company to trading on AIM. It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 12 October 2010.

Following the allotment of the new ordinary shares, the Company's issued share capital will consist of 81,532,463 Ordinary Shares of 10p each which entitle the holder to one vote per share. Therefore, the total number of voting rights is 81,532,463.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules.

The Company is also pleased to announce that Pictet Overseas Trust Corporation Limited have increased their stake in Immupharma to 3.02%.

Commenting on the developments, Chairman, Richard Warr, said:

"We are delighted that Pictet have increased their shareholding in ImmuPharma in excess of 3% and are pleased to have the continued support of such a prestigious Swiss bank."

For further information please contact:

ImmuPharma PLC +44 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer
Richard Warr, Chairman
Tracy Weimar, VP, Operations

Buchanan Communications +44 20 7466 5000

Lisa Baderoon, Mark Court

Panmure Gordon & Co., NOMAD & Broker 44 20 7459 3600

Andrew Burnett
Rakesh Sharma

Execution Noble & Co., Joint Broker +44 20 7456 9191

James Bromhead
Richard Crawley

Notes to Editors:

About ImmuPharma

ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by:

blockbuster potential in niche markets
low promotional costs in few specialised physicians and centres and
lower risk of drug development and lower development costs

ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections.

All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to "Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review" issued July 2004 and could therefore obtain their market authorization by 2010.

Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries.

In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates.

ImmuPharma has the option to commercialise its assets itself or to license them to other pharmaceutical companies at an earlier stage.

The products

Treatment of Lupus (IPP-201101)

This is a long-term treatment for Lupus, a chronic, life-threatening autoimmune disease where the immune system attacks healthy cells. There is currently no cure and existing medications only treat the symptoms whereas ImmuPharma's drug candidate has the potential to produce remission of the disease in a substantial proportion of patients.

Based on independent forecasts, the value of ImmuPharma's Lupus drug is estimated to be "substantial" with peak annual sales forecast to generate in excess of $4 billion.

Severe pain relief (IPP-102199)

ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year.

Antibiotic for MRSA and similar highly resistant infections (IPP-203101)

This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant.


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Additional Listing and Total Voting Rights Released 14:30 11-Oct-2010 Number 1946U14 FOR IMMEDIATE RELEASE London, 11 October 2010 ADDITIONAL LISTING AND TOTAL VOTING RIGHTS PICTET INCREASE HOLDING TO OVER 3% ImmuPharma plc (LSE:IMM) ("Immupharma" or the "Company"), the specialist discovery and development pharmaceutical company announces that following the exercise of options held by the liquidators to Dawnay Day Corporate Finance Limited, application has been made to the London Stock Exchange for the admission of 441,000 new ordinary shares of 10 pence each in the Company to trading on AIM. It is expected that these new ordinary shares, which will rank pari passu with the existing ordinary shares of the Company, will be admitted to trading on 12 October 2010. Following the allotment of the new ordinary shares, the Company's issued share capital will consist of 81,532,463 Ordinary Shares of 10p each which entitle the holder to one vote per share. Therefore, the total number of voting rights is 81,532,463. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FSA's Disclosure and Transparency Rules. The Company is also pleased to announce that Pictet Overseas Trust Corporation Limited have increased their stake in Immupharma to 3.02%. Commenting on the developments, Chairman, Richard Warr, said: "We are delighted that Pictet have increased their shareholding in ImmuPharma in excess of 3% and are pleased to have the continued support of such a prestigious Swiss bank." For further information please contact: ImmuPharma PLC +44 20 7152 4080 Dimitri Dimitriou, Chief Executive Officer Richard Warr, Chairman Tracy Weimar, VP, Operations Buchanan Communications +44 20 7466 5000 Lisa Baderoon, Mark Court Panmure Gordon & Co., NOMAD & Broker 44 20 7459 3600 Andrew Burnett Rakesh Sharma Execution Noble & Co., Joint Broker +44 20 7456 9191 James Bromhead Richard Crawley Notes to Editors: About ImmuPharma ImmuPharma PLC is a drug discovery and development company headquartered in London, UK and quoted on AIM of the London Stock Exchange (LSE:IMM). It has research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of novel drugs, largely based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases characterised by: blockbuster potential in niche markets low promotional costs in few specialised physicians and centres and lower risk of drug development and lower development costs ImmuPharma is a currently developing drug candidates for three different medical conditions, each of which would represent a significant breakthrough in its field. The furthest advanced drug candidate targets Lupus, a disease for which there is currently no cure or specific treatment. The other two address moderate to severe pain (such as that experienced by cancer sufferers and post-operative patients), and MRSA and similar severe hospital-acquired resistant infections. All three have significant sales potential as well as low marketing costs and a relatively low risk of development failure. One or more have the potential to be fast-tracked by the US Food and Drug Administration according to "Guidance for Industry: Fast Track Drug Development Programs - Designation, Development and Application Review" issued July 2004 and could therefore obtain their market authorization by 2010. Key to the potential success of ImmuPharma is its unique collaborative agreement with Centre National de la Recherche Scientifique, France's scientific research institution. This agreement grants ImmuPharma worldwide exclusive rights to exploit certain key discoveries. In addition to its three leading drug candidates, ImmuPharma has a drug development pipeline using its rights to a virtual chemical library of hundreds of thousands of molecules as well as an innovative technology for converting peptides to drug candidates. ImmuPharma has the option to commercialise its assets itself or to license them to other pharmaceutical companies at an earlier stage. The products Treatment of Lupus (IPP-201101) This is a long-term treatment for Lupus, a chronic, life-threatening autoimmune disease where the immune system attacks healthy cells. There is currently no cure and existing medications only treat the symptoms whereas ImmuPharma's drug candidate has the potential to produce remission of the disease in a substantial proportion of patients. Based on independent forecasts, the value of ImmuPharma's Lupus drug is estimated to be "substantial" with peak annual sales forecast to generate in excess of $4 billion. Severe pain relief (IPP-102199) ImmuPharma is developing a potential non-addictive compound for relieving moderate to severe pain, such as experienced by cancer sufferers and post-surgical patients. Most existing treatments are derived from the opiate morphine and tend to have serious side effects. ImmuPharma's new treatment is based on met-enkephalin, the body's internal analgesic. IPP-102199 is being developed to have major advantages over morphine such as longer pain relief duration and reduced side effects. The market for chronic opioids in the US currently exceeds $3.5 billion and is growing by more than 10 to 20 per cent a year. Antibiotic for MRSA and similar highly resistant infections (IPP-203101) This is a novel antibiotic to combat MRSA and other severe hospital-acquired, resistant infections which affect some two million people in the US, according to the US Centers for Disease Control and Prevention. ImmuPharma's drug candidate is targeted at disrupting the membrane potential of the bacterial pathogens. It is hoped this novel approach will reduce their potential to become resistant. ©2010 London Stock Exchange plc. All rights reserved